Il-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating cd3+cd56+ cells and downregulating regulatory t cells as well as il-35

Journal of Immunotherapy

Volumn 36, Issue 9, 2013, Pages 462-467

  Tao, Qianshan ^a   Chen, Tianping ^a   Tao, Lili ^a   Wang, Huiping ^a   Pan, Ying ^a   Xiong, Shudao ^a   Zhai, Zhimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

cytokine induced killer cells; IL 15, IL 35; IL 2; regulatory T cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 35; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MYELOID LEUKEMIA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

ADULT; ANTIGENS, CD3; ANTIGENS, CD56; CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKINS; K562 CELLS; LEUKEMIA; NATURAL KILLER T-CELLS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84887123089     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000001     Document Type: Article

References (27)

1. Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139-149.
2. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013;11:83. Doi: 10.1186/1479-5876-11-83.
3. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokineinduced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673-684.
4. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 2009;27:130-139.
5. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2011;137:305-310.
6. Stone RM, DeAngelo DJ, Janosova A, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008;83:771-777.
7. Dohnal AM, Witt V, Hü gel H, et al. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007;9:755-770. (Pubitemid 350226755)
8. Bonanno G, Iudicone P, Mariotti A, et al. Thymoglobulin, interferon-g and interleukin-2 efficiently expand cytokineinduced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129. Doi: 10.1186/1479-5876-8-129.
9. Hui KM. CIK cells-current status, clinical perspectives and future prospects-the good news. Expert Opin Biol Ther. 2012; 12:659-661.
10. Rettinger E, Kuçi S, Naumann I, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy. 2012;14:91-103.
11. Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front Oncol. 2012;2:32. Doi: 10. 3389/fonc.2012.00032.
12. Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114:3793-3802.
13. Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the anti-tumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 2007;27:317-326. (Pubitemid 46790817)
14. Lin G, Wang J, Lao X, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother. 2012;35:337-343.
15. Bardel E, Larousserie F, Charlot-Rabiega P, et al. Human CD4+CD25+Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol. 2008;181:6898-6905.
16. Wang Z, Liu JQ, Liu Z, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013;190:2415-2423.
17. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 2012;12:565-572.
18. Wang Y, Bo J, Dai HR, et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp Hematol. 2013;41:241-252.
19. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13-25.
20. Zheng SG, Wang J, Wang P, et al. IL-2 is essential for TGFbeta to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007;178:2018-2027
21. Pandiyan P, Zheng L, Ishihara S, et al. CD4+CD25+ Foxp3+ regulatory T cells induce cytokine deprivationmediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8:1353-1362. (Pubitemid 350131172)
22. Liu DV, Maier LM, Hafler DA, et al. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother. 2009;32:887-894.
23. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28:120-128. (Pubitemid 40328198)
24. Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11:1093-1101.
25. Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021-3029. (Pubitemid 350131282)
26. Castellani ML, Anogeianaki A, Felaco P, et al. IL-35, an anti-inflammatory cytokine which expands CD4+ CD25+ Treg Cells. J Biol Regul Homeost Agents. 2010; 24:131-135.
27. Chaturvedi V, Collison LW, Guy CS, et al. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol. 2011;186: 6661-6666.